Urine YKL-40 is associated with progressive acute kidney injury or death in hospitalized patients

BMC Nephrology

Chirag R Parikh²  Jack A Elias¹  Lloyd G Cantley⁴  Edward P Stern³  Isaac E Hall² 

[1] Division of Biology and Medicine, Brown University, Providence, RI, USA;Program of Applied Translational Research, Yale School of Medicine, 60 Temple Street, 6th Floor, Suite 6C, New Haven, CT 06510, USA;Centre for Nephrology, University College London/Royal Free London NHS Foundation Trust, London, UK;Section of Nephrology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA

关键词: YKL-40;    Net reclassification improvement;    Chitinase 3-like-1;    BRP-39;    Biomarker;    Acute kidney injury;   

Others  :  1082640
DOI  :  10.1186/1471-2369-15-133

 received in 2014-01-18, accepted in 2014-08-08,  发布年份 2014

【 摘 要 】

Background

A translational study in renal transplantation suggested YKL-40, a chitinase 3-like-1 gene product, plays an important role in acute kidney injury (AKI) and repair, but data are lacking about this protein in urine from native human kidneys.

Methods

This is an ancillary study to a single-center, prospective observational cohort of patients with clinically-defined AKI according to AKI Network serum creatinine criteria. We determined the association of YKL -40 ≥ 5 ng/ml, alone or combined with neutrophil gelatinase-associated lipocalin (NGAL), in urine collected on the first day of AKI with a clinically important composite outcome (progression to higher AKI stage and/or in-hospital death).

Results

YKL-40 was detectable in all 249 patients, but urinary concentrations were considerably lower than in previously measured deceased-donor kidney transplant recipients. Seventy-two patients (29%) progressed or died in-hospital, and YKL-40 ≥ 5 ng/ml had an adjusted odds ratio (95% confidence interval) for the outcome of 3.4 (1.5-7.7). The addition of YKL-40 to a clinical model for predicting the outcome resulted in a continuous net reclassification improvement of 29% (P = 0.04). In patients at high risk for the outcome based on NGAL concentrations in the upper quartile, YKL-40 further partitioned the cohort into moderate-risk and very high-risk groups.

Conclusions

Urine YKL-40 is associated with AKI progression and/or death in hospitalized patients and improves clinically determined risk reclassification. Combining YKL-40 with other AKI biomarkers like NGAL may further delineate progression risk, though additional studies are needed to determine whether YKL-40 has general applicability and to define its association with longer-term outcomes in AKI.

【 授权许可】

   
2014 Hall et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Hsu RK, McCulloch CE, Dudley RA, Lo LJ, Hsu CY: Temporal changes in incidence of dialysis-requiring AKI. J Am Soc Nephrol 2013, 24(1):37-42.
• [2]Singh TB, Rathore SS, Choudhury TA, Shukla VK, Singh DK, Prakash J: Hospital-acquired acute kidney injury in medical, surgical, and intensive care unit: A comparative study. Indian J Nephrol 2013, 23(1):24-29.
• [3]Susantitaphong P, Cruz DN, Cerda J, Abulfaraj M, Alqahtani F, Koulouridis I, Jaber BL, For the Acute Kidney Injury Advisory Group of the American Society of N: World Incidence of AKI: A Meta-Analysis. Clin J Am Soc Nephrol 2013, 8(9):1482-1493.
• [4]Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW: Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005, 16(11):3365-3370.
• [5]Coca SG, Singanamala S, Parikh CR: Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 2012, 81(5):442-448.
• [6]Coca SG, Yusuf B, Shlipak MG, Garg AX, Parikh CR: Long-term Risk of Mortality and Other Adverse Outcomes After Acute Kidney Injury: A Systematic Review and Meta-analysis. Am J Kidney Dis 2009, 53(6):961-973.
• [7]Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV, Tolwani AJ, Waikar SS, Weisbord SD: KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis 2013, 61(5):649-672.
• [8]Hall IE, Coca SG, Perazella MA, Eko UU, Luciano RL, Peter PR, Han WK, Parikh CR: Risk of poor outcomes with novel and traditional biomarkers at clinical AKI diagnosis. Clin J Am Soc Nephrol 2011, 6(12):2740-2749.
• [9]Hall IE, Doshi MD, Poggio ED, Parikh CR: A comparison of alternative serum biomarkers with creatinine for predicting allograft function after kidney transplantation. Transplantation 2011, 91(1):48-56.
• [10]Hall IE, Doshi MD, Reese PP, Marcus RJ, Thiessen-Philbrook H, Parikh CR: Association between peritransplant kidney injury biomarkers and 1-year allograft outcomes. Clin J Am Soc Nephrol 2012, 7(8):1224-1233.
• [11]Hall IE, Yarlagadda SG, Coca SG, Wang Z, Doshi M, Devarajan P, Han WK, Marcus RJ, Parikh CR: IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol 2010, 21(1):189-197.
• [12]Singer E, Marko L, Paragas N, Barasch J, Dragun D, Muller DN, Budde K, Schmidt-Ott KM: Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. Acta Physiol (Oxf) 2013, 207(4):663-672.
• [13]Schmidt IM, Hall IE, Kale S, Lee S, He CH, Lee Y, Chupp GL, Moeckel GW, Lee CG, Elias JA, Parikh CR, Cantley LG, et al.: Chitinase-Like Protein Brp-39/YKL-40 Modulates the Renal Response to Ischemic Injury and Predicts Delayed Allograft Function. J Am Soc Nephrol 2013, 24(2):309-319.
• [14]Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y: Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001, 93(14):1054-1061.
• [15]Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A, Acute Kidney Injury Network: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11(2):R31.
• [16]Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006, 145(4):247-254.
• [17]Lee JH, Kim SS, Kim IJ, Song SH, Kim YK, In Kim J, Jeon YK, Kim BH, Kwak IS: Clinical implication of plasma and urine YKL-40, as a proinflammatory biomarker, on early stage of nephropathy in type 2 diabetic patients. J Diabetes Complications 2012, 26(4):308-312.
• [18]Pennemans V, Rigo JM, Faes C, Reynders C, Penders J, Swennen Q: Establishment of reference values for novel urinary biomarkers for renal damage in the healthy population: are age and gender an issue? Clin Chem Lab Med 2013, 51(9):1795-1802.
• [19]Pencina MJ, D'Agostino RB Sr, Steyerberg EW: Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30(1):11-21.
• [20]Pencina MJ, D'Agostino RB, Pencina KM, Janssens AC, Greenland P: Interpreting incremental value of markers added to risk prediction models. Am J Epidemiol 2012, 176(6):473-481.
• [21]Lee CG, Da Silva CA, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, He CH, Takyar S, Elias JA: Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol 2011, 73:479-501. 73
• [22]Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A: Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009, 54(6):1012-1024.
• [23]Belcher JM, Edelstein CL, Parikh CR: Clinical applications of biomarkers for acute kidney injury. Am J Kidney Dis 2011, 57(6):930-940.
• [24]Doi K, Negishi K, Ishizu T, Katagiri D, Fujita T, Matsubara T, Yahagi N, Sugaya T, Noiri E: Evaluation of new acute kidney injury biomarkers in a mixed intensive care unit. Crit Care Med 2011, 39(11):2464-2469.
• [25]Parikh CR, Coca SG, Thiessen-Philbrook H, Shlipak MG, Koyner JL, Wang Z, Edelstein CL, Devarajan P, Patel UD, Zappitelli M, Krawczeski CD, Passik CS, Swaminathan M, Garg AX, for the TRIBE-AKI Consortium, et al.: Postoperative biomarkers predict acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc Nephrol 2011, 22(9):1748-1757.
• [26]Siew ED, Ware LB, Ikizler TA: Biological markers of acute kidney injury. J Am Soc Nephrol 2011, 22(5):810-820.
• [27]Koyner JL, Garg AX, Coca SG, Sint K, Thiessen-Philbrook H, Patel UD, Shlipak MG, Parikh CR, Consortium T-A: Biomarkers predict progression of acute kidney injury after cardiac surgery. J Am Soc Nephrol 2012, 23(5):905-914.
• [28]Parikh CR, Han G: Variation in performance of kidney injury biomarkers due to cause of acute kidney injury. Am J Kidney Dis 2013, 62(6):1023-1026.